These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20495924)

  • 1. [Recommendations of the German rheumatology society on the use of tocilizumab in rheumatoid arthritis].
    Gause A; Rubbert-Roth A; Michels H; Gaubitz M; Mayet WJ;
    Z Rheumatol; 2010 Jun; 69(4):365-72. PubMed ID: 20495924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal treatment of rheumatoid arthritis: EULAR recommendations for clinical practice.
    Bijlsma JW
    Pol Arch Med Wewn; 2010 Sep; 120(9):347-53. PubMed ID: 20864908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How closely does rheumatology treatment follow the guidelines?: ambition and reality].
    Zink A; Huscher D; Schneider M
    Z Rheumatol; 2010 Jun; 69(4):318-26. PubMed ID: 20490517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
    Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
    Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
    Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
    Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
    Ogata A; Kato Y; Higa S; Maeda K
    Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
    Nakashima Y; Kondo M; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Nagamine R; Nakashima H; Otsuka T; Saikawa I; Shono E; Suematsu E; Tsuru T; Wada K; Iwamoto Y
    Mod Rheumatol; 2010 Aug; 20(4):343-52. PubMed ID: 20480201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
    Kondo N; Fujisawa J; Endo N
    Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis.
    Koike R; Harigai M; Atsumi T; Amano K; Kawai S; Saito K; Saito T; Yamamura M; Matsubara T; Miyasaka N
    Mod Rheumatol; 2009; 19(4):351-7. PubMed ID: 19590933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
    Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
    Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
    Song SN; Yoshizaki K
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
    Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
    Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
    Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC
    Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.
    Hayakawa M; Izumi K; Higashida-Konishi M; Ushikubo M; Tsukamoto M; Akiya K; Araki K; Oshima H
    Rheumatol Int; 2019 Jan; 39(1):161-166. PubMed ID: 30357484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.